Document:

First Amendment to the Agreement for the Purchase and Sale of Blood Plasma

 Exhibit 10.1 
 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “***”. A
complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 
  
 DCI Management
Group, LLC 
 1019 Fort Salonga Road, Suite 109, Northport, NY 11768 
 Phone: 631-757-8401            Fax: 631-757-8364

 AMENDMENT No. 1 
 July 9, 2009 
 ViroPharma Biologics, Inc. 
 (Successor in interest to 
 Lev Pharmaceuticals,
Inc.) 
 730 Stockton Drive 
 Exton, PA
19341 
  

	 	Re:	First Amendment to that certain Agreement for the Purchase and Sale of Blood Plasma (the “Purchase Agreement”) dated July 12, 2007, between
Lev Pharmaceuticals, Inc. (“Lev Pharma”) and DCI Management Group LLC (“Seller”) 

 The purpose of this letter (this “Amendment”) is to confirm certain corporate changes relating to, and to effect certain amendments of, the Purchase Agreement. Any capitalized terms used in this Amendment that are
not otherwise defined herein shall have the meanings assigned to such terms in the Purchase Agreement. 
 Each of the parties to this Amendment
(each, a “Party,” and, collectively, the “Parties”) hereby acknowledges, consents to, and ratifies the following actions and amendments: 

	1.	Purchaser. On April 8, 2009, Lev Pharmaceuticals, Inc. merged with and into Lev Development Corp. and the surviving entity changed its name to ViroPharma
Biologics, Inc. Consequently, the parties to the Purchase Agreement are now Seller and ViroPharma Biologics, Inc. All references in the Purchase Agreement to “Purchaser,” “Lev Pharma, Inc.,” “Lev Development Corp.,”
“Lev Pharma,” and/or “Lev” shall be deemed to be references to ViroPharma Biologics, Inc. (“Purchaser”). 

  

	2.	New Notice Address. The notice address for Purchaser under Section 5.8 of the Purchase Agreement is hereby amended and changed to the following:

 ViroPharma Biologics, Inc. 
 730 Stockton Drive 
 Exton, Pennsylvania 19341 
 Attn: General Counsel 
  

	3.	Extension of Initial Term. The Parties hereby agree to extend the expiration date of the Initial Term set forth in Section 2.3 of the Purchase Agreement
from December 31, 2011 to December 31, 2013. The Parties will continue to have the “right of renewal” described in Section 5.3 of the Purchase Agreement, except that the date “2011” is hereby replaced with the date
“2013” in Section 5.3. In addition, any other reference in the Purchase Agreement to “December 2011” or “2011” (for example, at the end of Section 2.1 concerning Seller’s monthly production estimates)
shall be deemed to be a reference to “December 2013” or “2013,” as the context requires. 

  

	4.	Base Price and Additional Testing Costs. As used in the Purchase Agreement and this Amendment, the term “Base Price” means the per-liter
price at which Seller sells Blood Plasma to Purchaser, regardless of the Center from which the Blood Plasma is sourced. 

  

	 	(a)	 Base Price includes the cost of all serological testing required by the Specifications and/or Applicable Laws. For the avoidance of doubt, however,
Base Price does not include (i) 2 NAT testing (NAT-HIV-1 and NAT-HCV), for which Seller will charge Purchaser *** per liter in addition to the Base Price for so long as Purchaser requests Seller to have such testing performed; and (ii) 5
NAT testing (NAT-HIV-1, NAT-HCV, NAT-HBV, NAT-HAV, and PARVO), for which Seller will charge Purchaser *** per liter in addition to the Base Price for so long

  

 2 

	 	 
as Purchaser requests Seller to have such testing performed. All testing not performed directly by Seller will continue to be performed by NGI and coordinated by Seller. In addition, Seller will
continue to process such testing through Seller’s customer account with NGI until such time as Purchaser establishes its own customer account with NGI, at which point NGI will bill Purchaser directly for such testing.

  

	 	(b)	The sentence in Section 2.2.1 of the Purchase Agreement that addresses a minimum annual price increase to the Base Price between *** and *** as a result of market
conditions shall only apply to the calendar years 2010 and 2011. For calendar years 2012 and 2013, a minimum annual price increase or decrease resulting from market conditions shall be limited to a possible increase or decrease no greater than ***
of the Base Price, and only (i) if agreed to by the Parties by October 31st of the prior calendar year; and (ii) if consistent with the Parties’ reasonable evaluation of the market price for comparable blood plasma products as of
such date. 

  

	 	(c)	The Base Price for calendar year 2009 is *** per liter. 

  

	5.	New Centers. In the Purchase Agreement, Section 2.1 mentions a “New Center,” and Section 2.2.1 contains a paragraph with the heading,
“New Center.” The new center contemplated in those Sections is the center located in ***, and it will be referred to as, “NC-1.” In addition to NC-1, the Parties desire to discuss a second new center, which will be
referred to as “NC-2.” Any reference to a “new center” or the “New Center” in the Purchase Agreement, and the terms “New Center” and “New Centers” shall be
deemed to apply to each of NC-1 and NC-2, except where the context requires otherwise. In addition, the term “Center” shall also apply to each New Center, unless the context requires otherwise. For the avoidance of doubt, Seller shall not
have the right to open any New Center other than NC-1 and NC-2 and apply the Contingent Payment invoicing without the prior written consent of Purchaser, which Purchaser may withhold in its sole and absolute discretion. 

  

	 	(a)	Seller shall open NC-2 for the purpose of sourcing Blood Plasma for Purchaser. NC-2 shall be opened by Seller in the *** or the ***, depending upon Purchaser’s
preference, of which Purchaser shall deliver notice to Seller no later than ***. 

  

 3 

	 	(b)	The provisions relating to Contingent Payments under Section 2.2.1 of the Purchase Agreement shall apply to all New Centers, with the following modifications:
(i) the Parties hereby shorten the length of time allowed for approval from *** months to *** months for all New Centers, and all references to “*** months” are hereby amended to read, “*** months”; (ii) such *** month
period shall not be tolled, or affected in any way, including by application of the force majeure provisions set forth in Section 5.7 of the Purchase Agreement; (iii) Purchaser may, in its sole discretion and upon request from Seller no
later than 45 days prior to the expiration of the applicable *** month period, agree to extend the *** month period up to an additional *** months and, in exchange, the remaining *** of the applicable Plasma purchase then due shall be reduced *** to
*** and (iv) the *** month period applicable to NC-2 shall commence upon the date of the first invoice delivered by Seller to Purchaser. 

  

	 	(c)	Seller shall have the right, at its discretion, to use up to *** of the annual aggregate output of each New Center, measured by volume, for purposes other than the sale
of Blood Plasma to Purchaser, but (i) only in connection with Specialty plasma programs that do not compete in any way with Purchaser’s business; and (ii) only if, at the time that Seller contemplates doing so, Seller’s overall
supply to Purchaser of Blood Plasma for the calendar year to date, and Seller’s reasonable, good faith projection of its aggregate supply to Purchaser of Blood Plasma for the calendar year, are consistent with Seller’s volume and other
obligations to Purchaser for that Calendar Year. 

  

	6.	Volume Estimates. Seller hereby provides the following volume estimates; provided, however, Seller is obligated to provide at least *** liters of Blood Plasma to
Purchaser each calendar year (plus or minus ***): 

 Existing Center    New centers 

 

							
	 2009
	 	***	 	plus***	 	***
	 2010
	 	***	 	plus***	 	*** (Depending on date of NC-2 opening)

 By the end of *** all New Centers will be FDA licensed. 
  

			
	2011	    	***

  

 4 

			
	2012	    	***
	2013	    	***

  

	7.	Center Inspections. The provisions of Section 3.1 in the Purchase Agreement describing Purchaser’s right to conduct inspections of the Centers and
testing facilities, exercisable by Purchaser itself, or by any authorized representative, by the FDA, or by any state or local governmental agency, are hereby extended to include Purchaser, its affiliates, their respective contract parties, and
governmental officials of the European Union and its member states, including, without limitation, the European Medicines Agency and the European Commission, and their national counterparts. In addition, for the purposes of such provisions of
Section 3.1 of the Purchase Agreement and this Section 7 of this Amendment, the term “Applicable Laws” shall include the applicable laws, rules, regulations, requirements and directives of the European Union and its member
states, including the European Medicines Agency and the European Commission and their national counterparts. 

  

	8.	Payment Terms. Notwithstanding any provision in the Purchase Agreement to the contrary, the Parties hereby amend the payment terms for Blood Plasma such that
Purchaser shall be obligated to pay Seller net 10 days from the date of invoice, and each invoice shall bear a date that is no earlier than the date upon which Seller has delivered Blood Plasma to Purchaser corresponding to such invoice.

  

	9.	Dispositions of Centers. Seller shall not enter into agreement to sell or otherwise dispose of any Center without first (a) obligating the prospective
purchaser of such Center in writing to honor Seller’s commitments to Purchaser under the Purchase Agreement and (b) delivering written confirmation of such obligation to Purchaser. The foregoing provisions impose obligations and
restrictions upon Seller that are in addition to, not in lieu of, the obligations and restrictions applicable to Seller under the provisions of Section 5.15 of the Purchase Agreement. 

  

	10.	 Increase to Insurance Coverage. In light of the material purchases of Blood Plasma that Purchaser has purchased and contemplates purchasing from
Seller, the Parties hereby agree to amend the

  

 5 

	 	 
provisions of the last sentence of Section 5.5 of the Purchase Agreement such that (a) the amount ***” is deleted and replaced with ***”; and (b) the amount ***” is
deleted and replaced with “***.” In addition, Seller shall identify and maintain Purchaser as an additional insured on such policies, and shall provide a certificate of insurance confirming such policy limits and Purchaser’s status,
substantially simultaneously with signing this Amendment and thereafter annually and upon request from Purchaser. 

  

	11.	Relief from Purchase Requirements; Additional Termination Right. Notwithstanding any provision to the contrary in the Purchase Agreement, beginning in calendar
year 2010: (a) in the event that Purchaser determines that demand for its products made from Blood Plasma decreases by more than *** over calendar year 2009 levels, then for each *** decrease over such *** amount, Purchaser shall be excused
from purchasing *** of the amount of Blood Plasma that it otherwise would have been required to purchase from Seller in such calendar year; and (b) in the event that Purchaser determines that demand for its products made from Blood Plasma
ceases entirely, Purchaser shall have the right, upon not less than 30 days’ written notice to Seller, to terminate the Purchase Agreement in its entirety without liability for Blood Plasma not yet purchased; provided, however, that in the
event of termination, Buyer shall be responsible for purchase of Blood Plasma that was collected prior to the termination date. 

  

	12.	Certain Disclosures. Notwithstanding the provisions of Section 5.20 of the Purchase Agreement, Purchaser may disclose the terms of the Purchase Agreement to
the extent required, in the reasonable opinion of Purchaser’s or its affiliate’s legal counsel, to comply with applicable laws, including without limitation the rules and regulations promulgated by the United States Securities and Exchange
Commission (the “SEC”). Notwithstanding the foregoing, before disclosing the Purchase Agreement or any of its terms pursuant to this Section, Purchaser, or its affiliate, as the case may be, will use its commercially
reasonable efforts to seek confidential treatment of portions of this Agreement or such terms, as may be reasonably considered to contain sensitive business information. 

  

	13.	 No Other Changes; Execution. Except as explicitly set forth in this Amendment, no amendment or modification to the Purchase Agreement

  

 6 

	 	 
is hereby made. This Amendment may be executed in counterparts and delivered by facsimile or other electronic means. 

 Each Party has caused its duly authorized representative to sign on its behalf below to indicate its agreement to this Amendment as of the date first above
written. 
  

									
	DCI Management Group, LLC	 		 	ViroPharma Biologics, Inc.
					
	By:	 	/S/    IRA
LONDON        	 		 	By:	 	/S/    DANIEL B.
SOLAND        
		 	Ira London, CEO	 		 		 	Daniel B. Soland, President

  

 72000 Employee Stock Purchase Plan

 Exhibit 10.1 
 MARVELL TECHNOLOGY GROUP LTD. 
 2000 EMPLOYEE STOCK
PURCHASE PLAN 
 AS AMENDED AND RESTATED AS OF OCTOBER 22, 2009 
 1. Purpose. This Plan is intended to allow Employees of the Company and its Designated Subsidiaries to purchase Common Stock through
accumulated Payroll deductions. This Plan includes two components: a Code Section 423 Plan Component and a Non-423 Plan Component. The Company’s intention is to have the Code Section 423 Plan Component qualify as an “employee
stock purchase plan” under Section 423 of the Code (although the Company makes no undertaking or representation to maintain such qualification). The provisions of the Code Section 423 Plan Component, accordingly, will be construed so
as to extend and limit Plan participation in a uniform and nondiscriminatory basis consistent with the requirements of Section 423 of the Code. In addition, this Plan authorizes the grant of Purchase Rights under the Non-423 Plan Component that
do not qualify under Section 423 of the Code, pursuant to rules, procedures or sub-plans adopted by the Administrator that are designed to achieve tax, securities laws or other objectives for Participants and/or the Company. Except as otherwise
indicated, the Non-423 Plan Component will operate and be administered in the same manner as the Code Section 423 Plan Component. 
 2. Defined Terms. The meanings of defined terms (generally, capitalized terms) in this Plan are provided in Section 23 (“Glossary”). 
 3. Eligibility. 
 (a) Participation. Any person who is an Employee on
an Offering Date shall be eligible to participate in this Plan during the corresponding Offering Period, subject to the limitations in Sections 3(b) and 3(c). 
 (b) No Participation by Five-Percent Shareholders. Notwithstanding Section 3(a), an Employee shall not participate in this Plan during an Offering Period if immediately after the grant of a
Purchase Right on the Offering Date, the Employee (or any other person whose stock would be attributed to the Employee under Section 424(d) of the Code) would own stock possessing five percent or more of the total combined voting power or value
of all classes of stock of the Company or of any Subsidiary. For this purpose, an Employee is treated as owning stock that he or she could purchase by exercise of Purchase Rights or other options. 
 (c) $25,000 Annual Limitation. Notwithstanding Section 3(a), no Employee will be granted a Purchase Right under the Plan to the
extent that his or her rights to purchase stock under all employee stock purchase plans (as defined in Section 423 of the Code) of the Company or any Parent of the Company accrue at a rate, which exceeds $25,000 worth of stock (determined at
the Fair Market Value of the stock at the time such Purchase Right is granted) for each calendar year in which such Purchase Right is outstanding at any time, determined in accordance with Section 423 of the Code and the regulations thereunder.

 2000 ESPP (as amended and restated as of October 22, 2009) 

 4. Offering Periods. 
 (a) For Offering Periods That Commenced Prior to the Restatement Effective Date: Except as otherwise determined by the Administrator:

 (i) the first Offering Period under this Plan commenced on the first business day before the effective date of a firmly
underwritten initial public offering of Common Stock and ended on the last trading day of January of the second succeeding calendar year; 
 (ii) a new Offering Period began on each June 8 and December 8 prior to the Restatement Effective Date; 
 (iii) the duration of each Offering Period (other than the first Offering Period) shall be 24 months (measured from the first business day of the first month to the last business day of the 24th month);

 (iv) an Offering Period shall terminate on the first date that no Participant is enrolled in it; and 
 (v) all Participants enrolled in a 24 month Offering Period as of the Restatement Effective Date shall be automatically enrolled into a 6
month Offering Period as described in Section 4(b) at the end of the then-current Offering Period, in accordance with Section 5(b). For the avoidance of doubt, there shall be no further 24 month Offering Periods under this
Section 4(a) that commence on or following the Restatement Effective Date. 
 (b) For Offerings Periods That Commence On
or Following the Restatement Effective Date. Following the Restatement Effective Date, the Plan will be implemented by consecutive Offering Periods with a new Offering Period commencing June 8 and December 8 each year, or on such other
date as the Administrator will determine; provided, however that the first Offering Period on or following the Restatement Effective Date will commence on December 8, 2009 and end on June 7, 2010. The Administrator will have the
power to change the duration of Offering Periods (including the commencement dates thereof) with respect to future offerings without shareholder approval if such change is announced prior to the scheduled beginning of the first Offering Period to be
affected thereafter. 
 5. Participation. 
 (a) An Employee may become a Participant in this Plan by: (i) completing a subscription agreement, in such form as the Administrator may approve from time to time, and delivering it to the
Administrator or (ii) following an electronic enrollment procedure determined by the Administrator, in either event, by 5 p.m. Pacific time on the applicable Offering Date, unless another time for filing the subscription agreement is set
by the Administrator for all Employees with respect to a given Offering Period. For purposes herein, a subscription agreement and its analogous electronic enrollment form will both be referred to as the “subscription agreement.” The
subscription agreement shall authorize Payroll deductions pursuant to this Plan and shall have such other terms as the Administrator may specify from time to time. For the avoidance of doubt, a Participant may only be enrolled in one Offering Period
at any given time. 
  

 -2- 
 2000 ESPP (as amended and restated as of October 22, 2009) 

 (b) At the end of an Offering Period, each Participant in the Offering Period who remains an
Employee shall be automatically enrolled in the next succeeding Offering Period (a “Re-enrollment”) unless, in a manner and at a time specified by the Administrator, but in no event later than 5 p.m. Pacific time on the
Offering Date of such succeeding Offering Period, the Participant notifies the Administrator in writing that the Participant does not wish to be re-enrolled. Re-enrollment shall be at the withholding percentage specified in the Participant’s
most recent subscription agreement. No Participant shall be automatically re-enrolled whose participation has terminated by operation of Section 10. 
 (c) For Participants enrolled in an Offering Period that commenced prior to the Restatement Effective Date: 
 (i) If the Fair Market Value of a share of Common Stock on any Offering Date is less than it was on the first day of a then-concurrent Offering Period, each Participant in the concurrent Offering Period
shall automatically be withdrawn from such concurrent Offering Period and shall become a Participant in the commencing Offering Period, which shall be an Offering Period in accordance with 4(b). Participation shall be at the withholding percentage
specified in the Participant’s most recent (as of 5 p.m. Pacific time on the relevant Offering Date) subscription agreement. No Participant shall be automatically re-enrolled whose participation in this Plan has terminated by operation of
Section 10. 
 (ii) Any Participant enrolled in an Offering Period which commenced prior to the Restatement Effective Date
may elect to withdraw in such Offering Period and re-enroll in an Offering Period that commences after the Restatement Effective Date. Notwithstanding anything herein to the contrary, a Participant enrolled in an Offering Period that commenced prior
to the Restatement Effective Date must submit a new timely subscription agreement to be enrolled in an Offering Period that commences on or following the Restatement Effective Date. 
 6. Payroll Deductions. 
 (a) Payroll deductions under this Plan shall be in whole percentages, from a minimum of 1% up to a maximum (not to exceed 20%) established by the Administrator from time to time, as specified by the
Participant in his or her subscription agreement in effect on the first day of an Offering Period. Payroll deductions for a Participant shall begin with the first payroll payment date of the Offering Period and shall end with the last payroll
payment date of the Offering Period, unless sooner terminated by the Participant as provided in Section 10. 
 (b) A
Participant’s Payroll deductions shall be credited to his or her account under this Plan. A Participant may not make any additional payments into his or her account. 
 (c) A Participant may reduce his or her Payroll deductions by any whole percentage (but not below 1%) at any time during an Offering Period, which will become effective as soon as administratively
practicable. The Administrator may, in its sole discretion, limit the nature and/or number of Payroll deduction rate changes that may be made by Participants during any Offering Period, and may establish such other conditions or limitations as it
deems appropriate for Plan administration. A Participant may change his or her Payroll deductions for the next succeeding Offering Period, effective as of the next succeeding Offering Period, by delivering a new subscription agreement authorizing
the change to the Administrator by 5 p.m. Pacific time on the applicable Offering Date. 
  

 -3- 
 2000 ESPP (as amended and restated as of October 22, 2009) 

 (d) Notwithstanding the foregoing, to the extent necessary to comply with
Section 423(b)(8) of the Code and Section 3(c), a Participant’s Payroll deductions may be decreased to 0% at any time during the Offering Period. Subject to Section 423(b)(8) of the Code and Section 3(c) hereof, Payroll
deductions will recommence at the rate originally elected by the Participant effective as of the beginning of the first Offering Period scheduled to end in the following calendar year, unless terminated by the Participant as provided in
Section 10. 
 (e) Notwithstanding any provisions to the contrary in the Plan, the Administrator may allow Participants to
participate in the Plan via cash contributions instead of Payroll deductions if (i) Payroll deductions are not permitted under applicable local law, and (ii) the Participant is participating in the Non-423 Plan Component or the
Administrator determines that cash contributions are permissible under Section 423 of the Code. 
 7. Purchase
Rights. 
 (a) Grant of Purchase Rights. 
 (i) For Offering Periods That Commenced Prior to the Restatement Effective Date. On the Offering Date of each Offering Period, the
Participant shall be granted a Purchase Right to purchase during the Offering Period the number of shares of Common Stock determined by dividing (i) $25,000 multiplied by the number of (whole or part) calendar years in the Offering Period by
(ii) the Fair Market Value of a share of Common Stock on the Offering Date. 
 (ii) For Offerings Periods That Commence
On or Following the Restatement Effective Date. On the Offering Date of each Offering Period, each Participant will be granted a Purchase Right to purchase on each Purchase Date during such Offering Period (at the applicable purchase price) up
to a number of shares of Common Stock determined by dividing such Participant’s Payroll deductions accumulated prior to such Purchase Date and retained in the Participant’s account as of the Purchase Date by the applicable purchase price;
provided that in no event will a Participant be permitted to purchase during each Offering Period more than 7,500 shares of Common Stock (subject to any adjustment pursuant to Section 17), and provided further that such purchase will be subject
to the limitations set forth in Sections 3(b), 3(c) and 12. The Participant may accept the grant of such Purchase Right with respect to an Offering Period by electing to participate in the Plan in accordance with the requirements of Section 5.
The Administrator may, for future Offering Periods, increase or decrease, in its absolute discretion, the maximum number of shares of Common Stock that a Participant may purchase during each Offering Period, subject to the limitations set forth in
Sections 3(b), 3(c) and 12. Exercise of the Purchase Right will occur as provided in Section 8, unless the Participant has withdrawn pursuant to Section 10. The Purchase Right will expire on the last day of the Offering Period. 

 

 -4- 
 2000 ESPP (as amended and restated as of October 22, 2009) 

 (b) Terms of Purchase Rights. Except as otherwise determined by the Administrator,
each Purchase Right shall have the following terms: 
 (i) The per-share price of the shares subject to a Purchase Right shall
be 85% of the lower of the Fair Market Value of a share of Common Stock on (a) the Offering Date on which the Purchase Right was granted and (b) the Purchase Date. 
 (ii) Payment for shares purchased by exercise of Purchase Rights shall be made only through Payroll deductions under Section 6.

 (iii) Upon purchase or disposition of shares acquired by exercise of a Purchase Right, the Participant shall pay, or make
provision satisfactory to the Administrator for payment of, all tax (and similar) withholdings that the Administrator determines, in its discretion, are required due to the acquisition or disposition, including without limitation any such
withholding that the Administrator determines in its discretion is necessary to allow the Company and its Subsidiaries to claim tax deductions or other benefits in connection with the acquisition or disposition. 
 (iv) During his or her lifetime, a Participant’s Purchase Right is exercisable only by the Participant. 
 (v) Purchase Rights will in all respects be subject to the terms and conditions of this Plan, as interpreted by the Administrator from time
to time. 
 8. Purchase Dates; Purchase of Shares; Refund of Excess Cash. 
 (a) The Administrator shall establish one or more Purchase Dates for each Offering Period. Unless otherwise determined by the Administrator,
each June 7 and December 7 in an Offering Period shall be a Purchase Date. 
 (b) Except as otherwise determined by
the Administrator, and subject to subsection (c), below, each then-outstanding Purchase Right shall be exercised automatically on each Purchase Date, following addition to the Participant’s account of that day’s Payroll deductions, to
purchase the maximum number of full shares of Common Stock at the applicable price using the Participant’s accumulated Payroll deductions. No fractional shares of Common Stock will be purchased; any Payroll deductions accumulated in a
Participant’s account, which are not sufficient to purchase a full share will be promptly refunded to a Participant after a given Purchase Date. To the extent that Payroll deductions accumulate in a Participant’s account that exceed the
aggregate purchase price of the maximum amount of shares purchasable on a given Purchase Date, such excess amounts will be promptly refunded to a Participant after the given Purchase Date. 
 (c) For Participants enrolled in an Offering Period which commenced prior to the Restatement Effective Date, if on a Purchase Date the Fair
Market Value of a share of Common Stock is less than 75% of the Fair Market Value of a share of Common Stock on the immediately preceding Purchase Date (whether or not such preceding Purchase Date is in the same Offering Period) (the
“Benchmark Date”), then (except as otherwise determined by the Administrator): 
 (i) The maximum number of
shares that a Participant may purchase on the Purchase Date shall be determined by multiplying the Fair Market Value of a share of Common Stock on the Benchmark Date by 0.6375 and then dividing the Participant’s accumulated Payroll deductions
by the result. 
  

 -5- 
 2000 ESPP (as amended and restated as of October 22, 2009) 

 (ii) A maximum number of shares established pursuant to the clause (i) shall remain
the maximum number of shares purchasable by a Participant (including employees not enrolled on the Benchmark Date) on any subsequent Purchase Date until the Purchase Date on which the Fair Market Value of a share of Common Stock is at least 75% of
the Fair Market Value of a share of Common Stock on the Benchmark Date. 
 (iii) If a Participant was enrolled in an Offering
Period with a Purchase Date occurring on or after December 5, 2008 and such Participant was on a leave of absence during a purchase period when the initial calculation of the share limitation was calculated (“Initial Calculation
Period”) as set forth in clause (i) above, and as a result of the Participant being on a leave of absence was required to make reduced aggregate Payroll deductions, then, notwithstanding clause (ii) above, the Participant will be able
to purchase such amount of shares during the remainder of the Offering Period determined by multiplying the Fair Market Value of a share of Common Stock on the applicable Benchmark Date by 0.6375 and then dividing the Participant’s Assumed
Payroll Deductions as of the Purchase Date during the Initial Calculation Period by the result. For purposes of this Section 8(c)(iii), “Assume Payroll Deductions” shall mean the aggregate amount of Payroll deductions that would have
been made during the Initial Calculation Period had such Participant not taken a leave of absence and assumes a contribution for the remainder of the Initial Calculation Period of Payroll deductions by the Participant at the percentage in effect
immediately prior to the start of the Participant’s leave of absence. This calculation shall be effective for Purchase Dates on or after December 7, 2009. 
 (iv) Notwithstanding the foregoing, during the initial Offering Period under this Plan, the Benchmark Date shall be date of the beginning such Offering Period. 
 (v) Notwithstanding the foregoing, the final application of this Section 8(c) shall occur on the Purchase Date on which
Section 8(c)(ii) is triggered such that the Participant is no longer subject to the share limitation set forth in Section 8(c)(i). All Purchase Dates on or following such Purchase Date shall not be subject to this Section 8(c).

 (d) The shares purchased upon exercise of a Purchase Right shall be deemed to be transferred to the Participant on the
Purchase Date. 
 9. Registration and Delivery of Share Certificates. 
 (a) Shares purchased by a Participant under this Plan will be registered in the name of the Participant, or in the name of the Participant
and his or her spouse, or in the name of the Participant and joint tenant(s) (with right of survivorship), as designated by the Participant. 
  

 -6- 
 2000 ESPP (as amended and restated as of October 22, 2009) 

 (b) As soon as administratively feasible after each Purchase Date, the Company shall deliver
to the Participant a certificate representing the shares purchased upon exercise of a Purchase Right. If approved by the Administrator in its discretion, the Company may instead (i) deliver a certificate (or equivalent) to a broker for
crediting to the Participant’s account or (ii) make a notation in the Participant’s favor of non-certificated shares on the Company’s stock records. 
 10. Withdrawal; Termination of Employment. 
 (a) A Participant may withdraw
all, but not less than all, the Payroll deductions credited to his account under this Plan before a Purchase Date by giving written notice to the Administrator, in a form the Administrator prescribes from time to time, at least 15 days before the
Purchase Date. Payroll deductions will then cease as to the Participant, no purchase of shares will be made for the Participant on the Purchase Date, and all Payroll deductions then credited to the Participant’s account will be refunded
promptly. 
 (b) Upon termination of a Participant’s Continuous Employment for any reason, including retirement or death,
all Payroll deductions credited to the Participant’s account will be promptly refunded to the Participant or, in the case of death, to the person or persons entitled thereto under Section 14, and the Participant’s Purchase Right will
automatically terminate. 
 (c) A Participant’s withdrawal from an offering will not affect the Participant’s
eligibility to participate in a succeeding offering or in any similar plan that may be adopted by the Company. 
 11. Use of
Funds; No Interest. Amounts withheld from Participants under this Plan shall constitute general funds of the Company, may be used for any corporate purpose, and need not be segregated from other funds unless otherwise required under local law,
as determined by the Administrator (in which case, the affected Purchase Rights will be granted under the Non-423 Plan Component, if necessary). No interest shall accrue on a Participant’s Payroll deductions, except as may be required by
applicable law, as determined by the Administrator, for Participants in the Non-423 Plan Component (or the Code Section 423 Plan Component if permitted under Code Section 423). 
 12. Number of Shares Reserved. 
 (a) The following numbers of shares of Common Stock are reserved for issuance under this Plan, and such number may be issued at any time before termination of this Plan (for the avoidance of doubt, all
share numbers in this Section 12 reflect share numbers as adjusted for two separate 2 for 1 stock splits adopted by the Board in February 2004 and February 2006, respectively, and approved by the shareholders at the 2004 annual general meeting
of shareholders held on May 28, 2004 and the 2006 annual general meeting of shareholders held on June 9, 2006, respectively): 
 (i) Beginning the date of approval of this Plan by the shareholders of the Company, 4,000,000 shares of Common Stock; and 
  

 -7- 
 2000 ESPP (as amended and restated as of October 22, 2009) 

 (ii) Beginning the first business day of each calendar year starting January 1, 2010
or after, the lesser of an additional (A) 8,000,000 shares of Common Stock, or (B) 1.5% of the outstanding shares of capital stock on such date, or (C) an amount determined by the Board (provided that the amount approved by the Board
shall not be greater than (A) or (B)). As of the Restatement Effective Date, 53,871,612 shares had been added to this Plan through the operation of prior versions of this Section 12(a)(ii). As of the Restatement Effective Date, 39,138,247
shares were available for issuance under this Plan. 
 (b) If the total number of shares that would otherwise be subject to
Purchase Rights granted on an Offering Date exceeds the number of shares then available under this Plan (after deduction of all shares for which Purchase Rights have been exercised or are then exercisable), the Administrator shall make a pro-rata
allocation of the available shares in a manner that it determines to be as uniform and equitable as practicable. In such event, the Administrator shall give written notice of the reduction and allocation to each Participant. 
 (c) The Administrator may, in its discretion, transfer shares reserved for issuance under this Plan into a plan or plans of similar terms,
as approved by the Board, providing for the purchase of shares of Common Stock to employees of Designated Subsidiaries that do not (or do not thereafter) participate in this Plan. Such additional plans may, without limitation, provide for variances
from the terms of this Plan to take into account special circumstances (such as foreign legal restrictions) affecting the employees of the Designated Subsidiaries. 
 13. Administration. This Plan shall be administered by the Board or by such directors, officers, and employees of the Company as the Board may select from time to time (the
“Administrator”). All costs and expenses incurred in administering this Plan shall be paid by the Company, provided that any taxes applicable to an Employee’s participation in this Plan may be charged to the Employee by the
Company. The Administrator may make such rules and regulations as it deems necessary to administer this Plan and to interpret any provision of this Plan, and shall apply those rules and regulations so that all employees granted options under the
Plan have the same rights and privileges (except that the right to purchase stock under the Plan may bear a uniform relationship to total compensation). Notwithstanding any provision to the contrary in this Plan, the Administrator may adopt rules or
procedures relating to the operation and administration of the Non-423 Plan Component to accommodate the specific requirements of local laws and procedures for jurisdictions outside of the United States. Further, the Administrator is authorized to
adopt sub-plans applicable to particular Designated Subsidiaries or locations under the Non-423 Plan Component. The rules of such sub-plans may take precedence over other provisions of this Plan, with the exception of Section 12(a) hereof, but
unless otherwise superseded by the terms of such sub-plan, the provisions of this Plan shall govern the operation of such sub-plan. Any determination, decision, or action of the Administrator in connection with the construction, interpretation,
administration, or application of this Plan or any right granted under this Plan shall be final, conclusive, and binding upon all persons, and no member of the Administrator shall be liable for any such determination, decision, or action made in
good faith. 
 14. Designation of Beneficiary. 
 (a) A Participant may file a written designation of a beneficiary who is to receive any shares and cash, if any, from the Participant’s
account under this Plan in the event of the Participant’s death. 
  

 -8- 
 2000 ESPP (as amended and restated as of October 22, 2009) 

 (b) A designation of beneficiary may be changed by the Participant at any time by written
notice. In the event of the death of a Participant, and in the absence of a beneficiary validly designated under this Plan who is living at the time of the Participant’s death, the Administrator shall deliver such shares and/or cash to the
executor or administrator of the Participant’s estate, or if no such executor or administrator has been appointed (to the Administrator’s knowledge), the Administrator, in its discretion, may deliver such shares and/or cash to the spouse
or to any one or more dependents or relatives of the Participant or, if no spouse, dependent, or relative is known to the Administrator, then to such other person as the Administrator may designate. 
 15. Transferability. Neither Payroll deductions credited to a Participant’s account nor any rights with regard to the exercise
of a Purchase Right or to receive shares under this Plan may be assigned, transferred, pledged, or otherwise disposed of in any way (other than by will, the laws of descent and distribution, or as provided in Section 14) by the Participant. Any
such attempt at assignment, transfer, pledge, or other disposition shall be without effect, except that the Administrator may treat such act as an election to withdraw funds in accordance with Section 10. 
 16. Reports. Individual accounts will be maintained for each Participant in this Plan. Statements of account will be given to
participating Employees promptly following each Purchase Date, setting forth the amounts of Payroll deductions, per-share purchase price, number of shares purchased, and remaining cash balance, if any. 
 17. Adjustments upon Changes in Capitalization. 
 (a) Subject to any required action by the shareholders of the Company, the number of shares of Common Stock covered by each unexercised Purchase Right and the number of shares of Common Stock authorized
for issuance under this Plan but not yet been placed under a Purchase Right (collectively, the “Reserves”), as well as the price per share of Common Stock covered by each unexercised Purchase Right, shall be proportionately adjusted
for any change in the number of issued shares of Common Stock resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the Common Stock, or any change in the number of shares of Common Stock effected
without receipt of consideration by the Company (not counting shares issued upon conversion of convertible securities of the Company as “effected without receipt of consideration”). Such adjustment shall be made by the Board and shall be
final, binding, and conclusive. Except as expressly provided herein, no issue by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no consequent adjustment shall be made with
respect to, the number or price of shares of Common Stock subject to a Purchase Right. 
 (b) In the event of the proposed
dissolution or liquidation of the Company, the then-current Offering Period will terminate immediately before the consummation of the proposed action, unless otherwise provided by the Board. In the event of a proposed sale of all or substantially
all of the Company’s assets, or the merger of the Company with or into another corporation (if the Company’s shareholders own less than 50% of the total outstanding voting power in the surviving entity or a parent of the surviving entity
after the merger), each Purchase Right under this Plan shall be assumed or an equivalent purchase right shall be substituted by the successor corporation or a parent or subsidiary of the successor corporation, unless the successor corporation does
not agree to

  

 -9- 
 2000 ESPP (as amended and restated as of October 22, 2009) 

 
assume the Purchase Rights or to substitute equivalent purchase rights, in which case the Board may, in lieu of such assumption or substitution, accelerate the exercisability of Purchase Rights
and allow Purchase Rights to be exercisable as to shares as to which they would not otherwise be exercisable, on terms and for a period that the Board determines in its discretion. To the extent that the Board accelerates exercisability of Purchase
Rights as described above, it shall promptly so notify all Participants in writing. 
 (c) The Board may, in its discretion,
also make provision for adjusting the Reserves, as well as the price per share of Common Stock covered by each outstanding Purchase Right, if the Company effects one or more reorganizations, recapitalizations, rights offerings, or other increases or
reductions of shares of its outstanding Common Stock, or if the Company consolidates with or merges into any other corporation, in a transaction not otherwise covered by this Section 17. 
 18. Amendment or Termination. 
 (a) The Board may at any time terminate or amend this Plan. No amendment may be made without prior approval of the shareholders of the Company (obtained in the manner described in Section 20) if it
would increase the number of shares that may be issued under this Plan. 
 (b) The Board may elect to terminate any or all
outstanding Purchase Rights at any time, except to the extent that exercisability of such Purchase Rights has been accelerated pursuant to Section 17(b). If this Plan is terminated, the Board may also elect to terminate Purchase Rights upon
completion of the purchase of shares on the next Purchase Date or to permit Purchase Rights to expire in accordance with their terms (with participation to continue through such expiration dates). If Purchase Rights are terminated before expiration,
any funds contributed to this Plan that have not been used to purchase shares shall be refunded to Participants as soon as administratively feasible. 
 19. Notices. All notices or other communications by a Participant to the Company or the Administrator under or in connection with this Plan shall be deemed to have been duly given when received in
the form specified by the Administrator at the location, or by the person, designated by the Administrator for that purpose. 
 20. Shareholder Approval. This Plan was submitted to and approved by the shareholders of the Company for their approval within 12 months after the date this Plan was adopted by the Board. 
 21. Conditions upon Issuance of Shares. 
 (a) Shares shall not be issued with respect to a Purchase Right unless the exercise of such Purchase Right and the issuance and delivery of such shares pursuant thereto complies with all applicable
provisions of law, domestic or foreign, including, without limitation, the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, the rules and regulations promulgated thereunder, and the requirements of any stock
exchange upon which the shares may then be listed, and shall be further subject to the approval of counsel for the Company with respect to such compliance. 
  

 -10- 
 2000 ESPP (as amended and restated as of October 22, 2009) 

 (b) As a condition to the exercise of a Purchase Right, the Company may require the person
exercising such Purchase Right to represent and warrant at the time of any such exercise that the shares are being purchased only for investment and without any present intention to sell or distribute such shares if, in the opinion of counsel for
the Company, such a representation is required by any of the aforementioned applicable provisions of law. 
 22. Term of
Plan. This Plan became effective upon its initial approval by the shareholders of the Company on June 17, 2000 as described in Section 20. It shall continue in effect for a term of 20 years unless sooner terminated under
Section 18. 
 23. Glossary. The following definitions apply for purposes of this Plan: 
 (a) “Administrator” means the Board or the persons appointed by the Board to administer this Plan pursuant to
Section 13. 
 (b) “Board” means the Board of Directors of the Company. 
 (c) “Code” means the Internal Revenue Code of 1986, as amended. 
 (d) “Code Section 423 Plan Component” means the component of this Plan that is intended to meet the requirements set
forth in Section 423(b) of the Code, as amended. The provisions of the Code Section 423 Plan Component shall be construed, administered and enforced in accordance with Section 423(b). 
 (e) “Common Stock” means the Common Shares of the Company. 
 (f) “Company” means Marvell Technology Group Ltd., a Bermuda company. 
 (g) “Continuous Employment” means the absence of any interruption or termination of service as an Employee. Continuous
Employment shall not be considered interrupted in the case of a leave of absence agreed to in writing by the Company, provided that either (i) the leave does not exceed 90 days or (ii) re-employment upon expiration of the leave is
guaranteed by contract or statute. 
 (h) “Designated Subsidiaries” means the Subsidiaries that have been
designated by the Board from time to time in its sole discretion to participate in this Plan. The Administrator will determine whether Employees of any Designated Subsidiary shall participate in the Code Section 423 Plan Component or the
Non-423 Plan Component. 
 (i) “Employee” means any person, including an officer, who is customarily employed
for at least 20 hours per week and five months per year by the Company or one of its Designated Subsidiaries, other than an employee of a Designated Subsidiary under the Non-423 Plan Component, who, as of the Offering Date, is otherwise determined
ineligible for participation in the Non-423 Plan Component, at the discretion of the Administrator. Whether an individual qualifies as

  

 -11- 
 2000 ESPP (as amended and restated as of October 22, 2009) 

 
an Employee shall be determined by the Administrator, in its sole discretion, by reference to Section 3401(c) of the Code and the regulations promulgated thereunder; unless the Administrator
makes a contrary determination, the Employees of the Company shall, for all purposes of this Plan, be those individuals who satisfy the customary employment criteria set forth above and are carried as employees by the Company or a Designated
Subsidiary for regular payroll purposes. Notwithstanding the foregoing, for Purchase Rights granted under the Non-423 Plan Component, Employee shall also mean any other employee of a Designated Subsidiary to the extent that local law requires
participation in the Plan to be extended to such employee, as determined by the Administrator. 
 (j) “Fair Market
Value” means as, as of any date, the value of Common Stock as follows: 
 (i) If the Common Stock is quoted on an
established stock exchange or national market system, including without limitation the National Association of Securities Dealers, Inc. Automated Quotation (“NASDAQ”) National Market System, Fair Market Value shall be the closing sales
price (or the closing bid, if no sales are reported) as quoted on that exchange or system for the day of the determination, as reported in The Wall Street Journal or an equivalent source, or if the determination date is not a trading day, then on
the most recent preceding trading day; 
 (ii) If the Common Stock is quoted on NASDAQ (but not on the National Market System)
or regularly quoted by a recognized securities dealer but selling prices are not reported, Fair Market Value shall be the mean between the high bid and low asked prices for the Common Stock on the day of the determination, or on the most recent
preceding trading day if the determination date is not a trading day; or 
 (iii) In the absence of an established market for
the Common Stock, Fair Market Value shall be determined by the Administrator. 
 (k) “Non-423 Plan Component”
means a component of this Plan that is not intended to meet the requirements set forth in Section 423(b) of the Code, as amended. 
 (l) “Offering Date” means the first business day of an Offering Period. 
 (m) “Offering
Period” 
 (i) Prior to the Restatement Effective Date, “Offering Period” means a period established
by the Administrator pursuant to Section 4 during which Payroll deductions are accumulated from Participants and applied to the purchase of Common Stock. 
 (ii) As of the Restatement Effective Date, “Offering Period” means the periods of approximately 6 months during which a Purchase Right granted pursuant to the Plan may be exercised,
(A) commencing on June 8 of each year and terminating on December 7 of the following year, approximately 6 months later; and (B) commencing on December 8 of each year and terminating on the June 7, approximately 6
months later; provided, however, that the first Offering Period following the Restatement Effective Date will commence on December 8, 2009 and will end on June 7, 2010. The duration and timing of Offering Period may be changed pursuant to
Sections 4 and 18. 
  

 -12- 
 2000 ESPP (as amended and restated as of October 22, 2009) 

 (n) “Parent” means a “parent corporation,” whether now or
hereafter existing, as defined in Section 424(e) of the Code. 
 (o) “Participant” means an Employee who
has elected to participate, or has been deemed to participate by means of an automatic enrollment, in this Plan pursuant to Section 5. 
 (p) “Payroll” means all regular, straight-time gross earnings, exclusive of payments for overtime, shift premium, incentive compensation or payments, bonuses, and commissions. 

(q) “Plan” means this Marvell Technology Group Ltd. 2000 Employee Stock Purchase Plan, as amended and restated, which
includes a Code Section 423 Plan Component and a Non-423 Plan Component. 
 (r) “Purchase Date” means such
business days during each Offering Period as may be established by the Administrator for the purchase of Common Stock pursuant to Section 8. 
 (s) “Purchase Right” means a right to purchase Common Stock granted pursuant to Section 7. 
 (t) “Restatement Effective Date” means October 22, 2009, the date of the amendment and restatement of the Plan by the Board. 
 (u) “Subsidiary” means, from time to time, any corporation, domestic or foreign, of which not less than 50% of the voting
shares are held by the Company or another Subsidiary of the Company. 
  

 -13- 
 2000 ESPP (as amended and restated as of October 22, 2009)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}]]